西格列汀与阿卡波糖治疗初发2型糖尿病的疗效及安全性比较

Efficacy and safety comparison of sitagliptin and acarbose in the treatment of newly diagnosed type 2 diabetes mellitus

目的探讨西格列汀与阿卡波糖治疗初发2型糖尿病的疗效及安全性。方法收集我院2014年9月至2016年9月收治的初发2型糖尿病的患者70例作为本次研究对象,按照随机数字表法分为观察组和对照组,每组35例,观察组患者口服西格列汀,对照组患者口服阿卡波糖。比较两组患者治疗后的空腹血糖(FPG)、餐后2 h血糖(2h PG)、糖化血红蛋白(Hb Alc)及服药后的不良反应发生情况。结果治疗后,观察组的FPG[(5.33±1.46)mmo L/L]低于对照组[(6.45±0.76)mmo L/L],观察组2 h PG[(8.67±1.52)mmo L/L]低于对照组[(9.73±1.64)mmo L/L],观察组Hb Alc[(6.32±0.54)%]低于对照组[(7.21±0.84)%],差异均有统计学意义(P<0.05)。观察组患者的不良反应总发生率为2.86%低于对照组的不良反应总发生率14.29%,差异具有统计学意义(P<0.05)。结论西格列汀治疗初发2型糖尿病的疗效及安全性优于阿卡波糖,可显著降低糖尿病患者并发症的发生率,提高了患者的生活质量,服药简单、方便,可在临床推广使用。

Objective To evaluate the efficacy and safety of sitagliptin and acarbose in the treatment of newly diagnosed type 2 diabetes mellitus. Methods Seventy patients with newly diagnosed type 2 diabetes mellitus admitted in our hospital from September 2014 to September 2016 were selected and divided into the observation group（35 patients who were given sitagliptin） and the control group（35 patients who were given acarbose） according to the method of random number table.The levels of FPG, 2 h PG, Hb Alc and adverse reactions after treatment were compared between the two groups. Results After treatment, the FPG [（5.33±1.46） mmo L/L] in the observation group was lower than that in the control group [（6.45 ±0.76） mmo L/L], and the 2 h PG [（8.67 ±1.52） mmo L/L] in the observation group was lower than that of the control group（9.73±1.64） mmo L/L], and Hb Alc [（6.32±0.54） %] in the observation group was lower than that in the control group [（7.21±0.84） % ], the differences were statistically significant（P〈0.05）. The incidence of adverse reactions was 2.86% in the observation group, which was lower than 14.29% of the control group, the difference was statistically significant（P〈0.05）.Conclusion Sitagliptin in the treatment of newly diagnosed type 2 diabetes mellitus is superior to acarbose in the curative effect and safety, which can significantly reduce the incidence of complications in diabetic patients and improve the quality of life of the patients. The medication is simple and convenient and can be popularized in clinic.